CRISPR Makes Prostate Cancer Vulnerable to Immunotherapy

Researchers at the University of Rochester Medicine have made a significant breakthrough in using CRISPR technology to combat prostate cancer. They successfully used a CRISPR-based tool to make prostate tumors more vulnerable to immunotherapy, which helps the immune system identify and destroy cancer cells.

Most prostate tumors are “immune cold,” meaning they attract very few T cells, a type of immune cell. This limits the effectiveness of immunotherapy in these cases. By modifying the RNA inside prostate cancer cells using CRISPR technology, the scientists made the tumors more visible and attractive to cancer-fighting immune cells.

The mechanism behind this success is rooted in how cancer cells manipulate their own mRNAs to evade detection by the immune system. In normal cells, mRNAs carry genetic instructions from DNA to the cell’s protein-making machinery. However, in cancer cells, these instructions are often shortened, making them more stable and allowing them to produce large amounts of protein without proper regulation.

This phenomenon is not unique to prostate cancer; it has been observed in many types of tumors. The researchers’ discovery that CRISPR can restore the normal length of mRNAs in prostate cancer cells offers a potential solution for this problem. By forcing shortened mRNAs to re-lengthen, they reduced the production of SPSB1 protein, which destroys the MHC-1 complex necessary for immune cells to recognize tumor cells.

The implications of this research are far-reaching. If proven effective in humans, CRISPR-based therapies could revolutionize prostate cancer treatment and potentially other hard-to-treat tumors. The researchers achieved significant results without detectable off-target effects, a major breakthrough.

The next step will be to test the technology in other immune cold cancers, such as pancreatic cancer. With pilot funding secured from Wilmot Cancer Institute and Roswell Park Comprehensive Cancer Center, Wagner’s team is poised to take the next step towards making CRISPR a viable treatment option for patients.

Eric J. Wagner notes, “Cancer is super smart at evolving, but it’s not a magician.” This research demonstrates that with persistence and innovation, scientists can find ways to outsmart cancer’s defenses and restore hope for those fighting this disease.